Hansa Biopharma Shares Plunge After Anti-GBM Trial Misses Primary Endpoint

Hansa Biopharma AB

17/12/2025 08:50

** Shares in Hansa Biopharma HNSA.ST fell 27% after pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) did not meet primary endpoint

** ** The study in anti-GBM disease, a rare autoimmune condition, did not meet its primary goal as the control arm showed a surprisingly strong response

** Kempen Research sees the failure as a lost "building block for imlifidase beyond kidney transplant" but notes it was a small part of its valuation

** Focus now shifts to Hansa's plan to submit a Biologics License Application (BLA) for its main kidney transplant use to US regulators by the end of 2025

** This submission is key as it could pave the way for entry into the sizable US market as early as the second half of 2026, the brokerage adds

** Up to the previous session's close, shares were down 14.8% YTD

 (Reporting by Agnieszka Olenska)

 ((Agnieszka.olenska@thomsonreuters.com))